Fulgent Genetics, Inc. (FLGT) Tops Q3 EPS by 36c ; Offers Guidance

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of $0.14, $0.36 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $84.1 million versus the consensus estimate of $81.43 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2025 EPS of ~$0.30, versus the consensus of ($0.35). Fulgent Genetics, Inc. sees FY2025 revenue of ~$325 million, versus the consensus of $320.1 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Texas Capital Securities Downgrades Arcosa (ACA) to Hold